|
1) Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709-17
|
|
|
|
2) Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-21
|
|
|
|
|
|
3) Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006; 119: 912-9
|
|
|
|
|
|
4) Shibata S, Nagase M, Yoshida S, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. (in press)
|
|
|
|
|
|
5) Ribstein J, Du Cailar G, Fesler P, et al. Relative glomerular hyperfiltration in primary aldostero-nism. J Am Soc Nephrol. 2005; 16: 1320-5
|
|
|
|
|
|
6) Rossi GP, Bernini G, Desideri G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006; 48: 232-8
|
|
|
|
|
|
7) Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007; 3: 486-92
|
|
|
|
|
|
8) Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003; 41: 64-8
|
|
|
|
|
|
9) Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006; 70: 2116-23
|
|
|
|
|
|
10) Quinkler M, Zehnder D, Eardley KS, et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation. 2005; 112: 1435-43
|
|
|
|
|
|
11) Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003; 63: 1791-800
|
|
|
|
|
|
12) Nishiyama A, Yao L, Nagai Y, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension. 2004; 43: 841-8
|
|
|
|
|
|
13) Rocha R, Chander PN, Zuckerman A, et al. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension. 1999; 33: 232-7
|
|
|
|
|
|
14) Fiebeler A, Nussberger J, Shagdarsuren E, et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation. 2005; 111: 3087-94
|
|
|
|
|
|
15) Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev. 2003; 83: 253-307
|
|
|
|
|
|
16) Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mecha-nisms of proteinuria. N Engl J Med. 2006; 354: 1387-401
|
|
|
|
|
|
17) Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997; 99: 342-8
|
|
|
|
|
|
18) Nagase M, Shibata S, Yoshida S, et al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension. 2006; 47: 1084-93
|
|
|
|
|
|
19) Shibata S, Nagase M, Yoshida S, et al. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension. 2007; 49: 355-64
|
|
|
|
|
|
20) Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U. S. adults. Ann Intern Med. 2004; 140: 167-74
|
|
|
|
|
|
21) Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005; 16: 2134-40
|
|
|
|
|
|
22) Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006; 48: 239-45
|
|
|
|
|
|
23) Kidambi S, Kotchen JM, Grim CE, et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007; 49: 704-11
|
|
|
|
|
|
24) Russo P, Lauria F, Loguercio M, et al. -344C/T Variant in the promoter of the aldosterone synthase gene (CYP11B2) is associated with metabolic syndrome in men. Am J Hypertens. 2007; 20: 218-22
|
|
|
|
|
|
25) Ingelsson E, Pencina MJ, Tofler GH, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 2007; 116: 984-92
|
|
|
|
|
|
26) Nagase M, Yoshida S, Shibata S, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006; 17: 3438-46
|
|
|
|
|
|
27) He J, Ogden LG, Bazzano LA, et al. Dietary sodium intake and incidence of congestive heart failure in overweight US men and women: first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Arch Intern Med. 2002; 162: 1619-24
|
|
|
|
|
|
28) Verhave JC, Hillege HL, Burgerhof JG, et al. Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med. 2004; 256: 324-30
|
|
|
|
|
|
29) Nagase M, Matsui H, Shibata S, et al. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension. 2007; 50: 877-83
|
|
|
|
|
|
30) Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol. 2004; 217: 53-8
|
|
|
|
|
|
31) Togawa A, Miyoshi J, Ishizaki H, et al. Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha. Oncogene. 1999; 18: 5373-80
|
|
|
|
|
|
32) Ushio-Fukai M. Localizing NADPH oxidase-derived ROS. Sci STKE. 2006; 2006: re8
|
|
|
|
|
|
33) Wu X, Tu X, Joeng KS, et al. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell. 2008; 133: 340-53
|
|
|
|
|